Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...

Axsome Therapeutics (AXSM) announced that it has entered into a settlement agreement with Hikma Pharmaceuticals (HKMPF), resolving patent ...

Axsome Therapeutics (AXSM) stock gains as company settles patent dispute with Hikma (HKMPF) over sleep therapy Sunosi. Read ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central ...

Looking ahead, revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 5.3% growth forecast ...

Hikma's generics business, grew 9 per cent to $1.026 billion, surpassing the $1 billion revenue mark for the first time.

In a report released today, James Gordon from J.P. Morgan maintained a Buy rating on Hikma Pharmaceuticals (HIK – Research Report), with a ...

The Group reported revenue growth of 9% (9% in constant currency) to $3.127 billion compared to $2.875 billion in 2023) ...

Hikma Pharmaceuticals PLC HIK shares dropped 6.18% to £21.54 Wednesday, on what proved to be an all-around positive trading ...

We maintain our fair value estimate of $187 per share. Xywav (for excessive daytime sleepiness), Epidiolex (for childhood epilepsy), and Rylaze (for leukemia) have continued to be Jazz’s primary ...